PFIZER ANNOUNCES EXECUTIVE APPOINTMENTS.
/FIRST AND FINAL ADD -- NY066 -- PFIZER/ EDMUND T. PRATT, JR. Edmund T. Pratt, Jr. is chairman of the board of Pfizer Inc. He joined Pfizer as controller in 1964 and moved to Pfizer International in 1967, where he became chairman of the board and president in 1969. Pratt became president of Pfizer in 1971 and chairman and chief executive officer in 1972. He stepped down as chief executive officer in May of 1991. Pratt began his career with International Business Machines Corporation in 1949 and served as controller of IBM World Trade Corporation from 1958 to 1962. During the Kennedy Administration he served as Assistant Secretary of the Army for Financial Management. Born in Savannah, Ga., in 1927 he graduated from Duke University in 1947 with a B.S. degree in electrical engineering and received an M.B.A. from the Wharton School in 1949. Pratt is a director of General Motors Corporation, International Paper Company, The Chase Manhattan Corporation, and The Chase Manhattan Bank, N.A. He is immediate past chairman of The Business Roundtable. He is also a past chairman of both the President's Advisory Committee for Trade Policy and Negotiations and the Emergency Committee for American Trade. He is a member of The Business Council. Pratt is also past chairman of The Business Council of New York State, Governor Cuomo's Business Advisory Board, and was a member of the boards of the New York Chamber of Commerce and Industry and the New York City Partnership. WILLIAM C. STEERE, JR. William C. Steere, Jr. is president and chief executive officer of Pfizer Inc. He has been a member of the board of directors since 1987. Steere began his career with Pfizer in 1959 as a medical service representative. His transition from sales representative to sales management to product management was rapid. His 1969 promotion to director of marketing for Pfizer Latin America expanded his business experience to include international marketing. He then returned to domestic pharmaceutical management as vice president of marketing for the Roerig Division. In 1972, he was named general manager of Roerig and vice president, Pfizer Pharmaceuticals. He was promoted to vice president and general manager for Pfizer Laboratories in 1980. Two years later Steere was appointed executive vice president of Pfizer Pharmaceuticals and elected a corporate vice president of Pfizer Inc in 1983. He was named president of Pfizer Pharmaceuticals Group in February 1986. He was elected to his present position in February 1991. In April 1989 he was elected to the board of directors of the Pharmaceutical Manufacturers Association. His other outside board memberships include the New York Botanical Garden, the American Diabetes Association, the Connecticut Mutual Life Insurance Co., the Regional Plan Association, the U.S. Council for International Business and WNET - Thirteen. Steere graduated from Stanford University with a B.A. in Biology in 1959. He and his wife, Lynda, have three sons and live in Darien,
EDWARD C. BESSEY Edward C. Bessey was elected an executive vice president of Pfizer Inc in February 1991. He is also president and chief executive officer of Pfizer Hospital Products Group, a position he has held since July 1982. In March 1991, he assumed the additional responsibility for Pfizer Consumer Products Group. Bessey joined Pfizer in 1964 as a marketing assistant in the Pfizer Laboratories Division. After a field assignment he returned to headquarters and was named assistant product manager in 1965, product manager in 1967, and group product manager in 1968. He served as vice president and director of operations for Pfizer Laboratories from 1972 to 1977, when he was named executive vice president of Pfizer Europe. In that post, he was responsible for the pharmaceutical and agricultural businesses in France, Italy, Belgium, the Nordic countries, Eastern Europe and the United Kingdom. In addition, he managed the pharmaceutical development and medical functions for Pfizer Europe at the European Management Center located in Brussels, Belgium. He returned to the United States in 1980 as executive vice president of Pharmaceuticals and Diagnostics, and joined the Hospital Products Group the following year. He was elected to Pfizer's board of directors in 1987. In January 1989, Bessey was elected a senior vice president of Pfizer Inc. Bessey was graduated from Dartmouth College in 1957 with a B.A. degree and received an M.B.A. from Dartmouth's Amos Tuck School in 1961. He served as an officer in the U.S. Navy from 1957-1960. He is a member of the board of directors of Pfizer Inc, chairman of the board of directors of Pfizer Hospital Products Group, a member of the board of directors of the Health Industry Manufacturers Association, a member of the board of directors of the U.S.O. of Metropolitan New York, as well as a director of the United Way of Tri-State. In addition, he is a member of the National Advisory Council on Health Care Policy, Research and Evaluation of the Agency for Health Care Policy Research as well as the National Industrial Advisory Council of Opportunities Industrialization Centers of America. He is also a member of the Economics Club of New York. Bessey and his wife, Jill, reside in New Canaan, Conn. JEAN-PAUL VALLES Jean-Paul Valles, Ph.D., is executive vice president, Pfizer Inc. Valles joined Pfizer in 1968 as an economist and assistant to the chairman. In 1970, he was appointed director of corporate planning and information services, and in 1972 was elected controller of the company. In April 1980, he was elected to the board of directors of Pfizer Inc. He became vice president-finance in June 1980 and was elected senior vice president-finance in January 1989. On April 1, 1989, he was given responsibility for Pfizer Specialty Minerals Group. On Aug. 1, 1990 he was elected senior vice president and assumed the additional responsibility for the company's Animal Health Group with Finance now reporting to him. He was elected to his present position on Feb. 1, 1991 when he also undertook responsibility for the Pfizer Specialty Chemicals Group. Born in Paris, France, Valles received his bachelor's degree in mathematics in 1956 and was graduated from Ecole Superieure de Commerce de Paris in 1960. He earned his M.B.A. from New York University in 1961 and his Ph.D. in 1967, also from NYU. Valles is a director of: Junior Achievement of New York Inc., the National Association of Manufacturers, the Business Council of New York State, Inc. and the New York Chapter of the French-American Chamber of Commerce in the U.S., Inc. He is a member of the American Economic Association, the Financial Executives Institute and the Financial Accounting Standards Advisory Council of the Financial Accounting Foundation. Valles also serves on the financial council of the
American Management Association.
Valles and his wife, Carol Ann, live in Bedford, N.Y. They have three children: Alain, Suzanne and Sandra. BARRY M. BLOOM, Ph.D. Barry M. Bloom, Ph.D., is senior vice president, Research and Development, and a member of the board of directors of Pfizer Inc. His responsibilities include the Central Research, Licensing and Development, and Quality Control Divisions of the company. Bloom began his career with Pfizer in 1952 as a research chemist. He later served as director of Medicinal Products Research and Development and in 1969 became vice president, Medicinal Products Research and Development of Pfizer Pharmaceuticals. He was named president of Pfizer Central Research, and elected a corporate vice president in 1971, a member of the board of directors in 1973, and a member of the Corporate Management Committee in 1984. He was named senior vice president of Pfizer Inc in September 1990. A graduate of the Massachusetts Institute of Technology, Bloom received his S.B. in 1948 and his Ph.D. in organic chemistry in 1951, after which he was a National Research Council Postdoctoral Fellow at the University of Wisconsin. He is also a graduate of the Senior Executive Program of the Sloan School of Management at M.I.T. Bloom is a member of the board of directors of Oncogene Science Inc., Southern New England Telecommunications Corp. and the Connecticut Business and Industry Association. He is a member of the board of managers of the Lawrence and Memorial Hospital (New London, Conn.). In the past, Bloom was a member of the U.S. Congressional Commission on the Federal Drug Approval Process and the Pharmaceutical Manufacturers Association (PMA) Commission on Drugs for Rare Diseases. He is a former chairman of the PMA R&D Section Steering Committee, was a member of the Massachusetts Institute of Technology's Corporate Visiting Committee for the departments of Chemistry and Biology and served on the State of Connecticut Technology Advisory Board. Bloom and his wife, Joan, live in Lyme, Conn. HENRY A. McKINNELL, JR. Henry A. McKinnell, Jr., Ph.D., is vice president-finance and chief financial officer of Pfizer Inc. McKinnell joined Pfizer in 1971 as assistant to the president of Pfizer Taito in Tokyo. Over the years, he has held positions of increasing responsibility for Pfizer International subsidiaries. McKinnell served in Iran as country manager of Iran/Afghanistan from 1973 to 1977; vice president and area manager of Pfizer Asia from 1977 to 1979; executive vice president of Pfizer Asia from 1979 to 1981; and president of Pfizer Asia from 1981 to 1984. McKinnell was stationed in Hong Kong during his service with Pfizer Asia. McKinnell was named vice president of Corporate Strategic Planning for Pfizer Inc in 1984 and a corporate officer and vice president of Pfizer Inc in 1986. He was appointed to his present position in 1990. Born in 1943, McKinnell holds a bachelor's degree in Commerce from the University of British Columbia, an M.B.A. and a Ph.D. from the Stanford University Graduate School of Business. McKinnell serves as a director of the Miami Heart Institute, the National Council on Crime and Delinquency, and the Washington, D.C.- based Private Sector Council. He is a trustee of the Committee for Economic Development (CED) and was appointed in 1988 by Governor Mario Cuomo to the New York State Government Advisory Council. He is also a member of the Economic Club of New York, the Retirement Policy Institute, the Association for Corporate Growth and the Planning Forum. He and his wife, Guri, live in Greenwich, Conn. They have four children. ROBERT NEIMETH Robert Neimeth is chairman, president and chief executive officer of Pfizer International subsidiaries and a vice president of Pfizer Inc. A graduate of Cornell University, Neimeth joined Pfizer International in 1962. After various assignments in New York, Europe and Nigeria, he was appointed country manager of Nigeria in 1965. In 1968, he became pharmaceutical development director for Pfizer Asia, was named vice president in 1970 and became president of Pfizer Asia in 1972. In 1977, Neimeth left Pfizer International to become vice president of Pfizer Pharmaceuticals and director of operations of Pfizer Laboratories. Three years later, he rejoined International when he was appointed president of Pfizer Europe. In 1984, he was named executive vice president of Pfizer International. He was named to his present position in June 1990. Neimeth is a member of the Business and Industry Advisory Committee (BIAC) where he serves as chairman of the Trade Committee. He serves on the Economic Policy Committee of the United Nations Association of the U.S.A. and is a member of the Corporate Affairs Committee of The Japan Society. He is also a member of the Executive Committee of the International Section of the Pharmaceutical Manufacturers Association and many other trade and business associations. Neimeth is also a national trustee of Boys and Girls Clubs of America. -0- 1/23/92 AA NY066 /END FIRST AND FINAL ADD/ (PFE) CO: Pfizer Inc ST: New York IN: MTC SU: PER FC -- NY066A -- 2968 01/23/92 15:59 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 23, 1992|
|Previous Article:||NEW CHIEF EXECUTIVE NAMED AT SMITH, HINCHMAN & GRYLLS, INC., NATION'S OLDEST ARCHITECTURAL FIRM|
|Next Article:||CHEMICAL BANKING CORPORATION COMPLETES OFFERING OF 57.5 MILLION COMMON SHARES AT $27.25 PER SHARE FOR GROSS PROCEEDS OF $1.57 BILLION|